HF2624

Purpose of the Bill

The bill aims to update and amend the provisions related to the Minnesota Prescription Monitoring Program (PMP), which is designed to monitor and regulate the prescribing and dispensing of controlled substances. The revisions target enhancing data accuracy, strengthening oversight, and increasing accessibility for authorized users.

Main Provisions

• Definitions Updates: New definitions are clarified for terms like "controlled reportable substances," which now include substances like butalbital and gabapentin, and FDA-approved opioid antagonists.

• Electronic Reporting System: The Minnesota State Board of Pharmacy is tasked with maintaining an electronic prescription monitoring system, allowing for contracted technical assistance to manage the system.

• Data Reporting Requirements: Dispensers are required to report detailed data for each prescription, such as prescriber and patient details, drug details, and dispensing dates. Dispensers must notify patients about these reporting requirements.

• Use of Data: The data from the PMP will be used to identify suspicious prescription patterns and unauthorized prescriptions. Careful measures are included to ensure the data is encrypted and only accessible to authorized users for specified terms.

• Access Procedures: Defines permissible users who can access PMP data, including healthcare providers and pharmacists, under specific conditions and for legitimate medical purposes. Establishes procedures for prescribers to regularly check on patients receiving ongoing opioid prescriptions.

• Auditing and Security: Implements regular audits of access to ensure compliance with permissible use, while establishing strict security measures for data access. Requires permissible users to audit their agents' use of data.

• Patient Rights: Allows patients to request access to their PMP data and see who has accessed their prescription history.

Significant Changes to Existing Law

• Enhanced Controlled Substance Monitoring: Expands the list of substances monitored and specifies the inclusion of specific FDA-approved substances.

• Increased Oversight: Introduces stronger auditing processes and detailed reporting requirements to ensure correct data usage.

• Privacy and Access: Updates privacy controls, maintaining patient confidentiality while allowing necessary access to prescribers and pharmacists.

• Mandatory Prescriber Registration: All prescribers authorized to prescribe controlled substances must register with the PMP, ensuring widespread adoption of monitoring practices.

Relevant Terms

controlled substances, prescription monitoring, butalbital, gabapentin, opioid antagonists, Minnesota State Board of Pharmacy, electronic reporting system, permissible users, data encryption, auditing, patient access, privacy controls, prescriber registration.